Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma: early-phase trial registry

1 of 5 indexed Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma: 5 US clinical trials tracked, 1 recruiting.

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is AIDS Malignancy Consortium, running 1 of these trials.

Enrollment posture brief

Registry condition mature-t-cell-and-nk-cell-non-hodgkin-lymphoma

OPEN 1 | RECR 20% | LATE 0 | EARLY 3 | RANK #3391 | SPON 1

Volume-matched condition peers

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Mature T-Cell and NK-Cel (th…20%
Open-enrollment share among volume-matched conditions near Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma research.

    AIDS Malignancy Consortium accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 48 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 21

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1

Top Sponsors

AIDS Malignancy Consortium 1 trials
Emory University 1 trials
City of Hope Medical Center 1 trials
Mayo Clinic 1 trials
National Cancer Institute (NCI) 1 trials

Named interventions

Most-linked intervention names on Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
3 trials
Etoposide Drug
2 trials
Mitoxantrone Hydrochloride Drug
1 trials
Inactivated Influenza Vaccine Biological
1 trials
Pegaspargase Drug
1 trials
Autologous Hematopoietic Stem Cell Transplantation Procedure
1 trials
Methotrexate Drug
1 trials
Carmustine Drug
1 trials

US sites by state

Facility locations filed on Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.

Georgia 3 trials
California 3 trials
Ohio 2 trials
New York 2 trials
Missouri 2 trials
Minnesota 2 trials
Arizona 2 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • AIDS Malignancy Consortium sponsors the most Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See AIDS Malignancy Consortium's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma condition card totals 5 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.